[{"Assets_0_Q1_USD":1228300000.0,"CommonStockSharesConverted_0_Q1_shares":69200000.0,"CommonStockSharesOutstanding_0_Q1_shares":69200000.0,"EarningsPerShareBasic_1_Q1_USD":1.18,"EarningsPerShareDiluted_1_Q1_USD":1.15,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":23500000.0,"NetIncomeLossConverted_1_Q1_USD":81000000.0,"RevenuesConverted_1_Q1_USD":190200000.0,"StockholdersEquity_0_Q1_USD":870900000.0,"StockholdersEquityConverted_0_Q1_USD":870600000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":70400000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":68600000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2018.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20171108"}]